Emerging treatment therapies targeting conditions earlier in the care continuum have been impacting demand for Nevro’s prized SCS portfolio. The company’s own SI offerings are solutions for ...

U.S. permanent implant procedures decreased by 7.0% compared with the fourth quarter of 2023, and U.S. trial ... treatment. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform ...